Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.

Lancet Diabetes EndocrinolAug 7, 2026 (epub)
Clinical ResearchNephrologyEndocrinology

Johannes F E Mann, Sunil V Badve, Florian M M Baeres et al.

✦ AI-curated · Sources linked

In 30 seconds

This pooled analysis of participant-level data from the SELECT, FLOW, and SOUL trials evaluated the effects of semaglutide on kidney outcomes in individuals with type 2 diabetes and chronic kidney disease. The study found that semaglutide significantly reduced the risk of major kidney outcomes, with a hazard ratio of 0.84 for the primary kidney composite outcome compared to placebo, across a mean follow-up of 39.5-47.5 months.

Key findings

  • Semaglutide reduced the risk of the primary kidney composite outcome with a hazard ratio of 0.84.
  • First events of a narrower secondary kidney composite were reduced with semaglutide (347 vs 416 events).
  • Safety outcomes were similar between semaglutide and placebo groups, with fewer serious adverse events in the semaglutide group.

Why it matters

The findings support the use of semaglutide in managing kidney outcomes in patients with cardio-kidney-metabolic disease, highlighting its potential benefits beyond glycemic control and weight management.

Source

PubMed · PMID 42567173

Published in Lancet Diabetes Endocrinol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.